A better understanding of what actually happens in ischemic brain events is leading to therapies that limit permanent brain damage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Del Zoppo, G.J. 1995. Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral blood flow. J. Int. Med. 237: 79–88.
Garcia. J.H., et al. 1996. Ischemic stroke and incomplete infarction. Stroke 27: 761–765.
Siesjî, B.K., et al. 1995. Glutamate, calcium and free radicals as mediators of ischemic brain damage. Ann. Thoracic Surg. 59: 1316–1320.
Author information
Author notes
Robert S. Schehr is a consultant in biotechnology and pharmaceutical development. He is founder of the Science & Technology Group, P.O. Box 109, Lake Placid, NY. He can be reached at 75361.1240@compuserve.com.
- Robert S. Schehr
Rights and permissions
About this article
Cite this article
Schehr, R. New treatments for acute stroke. Nat Biotechnol 14, 1549–1554 (1996). https://doi.org/10.1038/nbt1196-1549
Issue Date:
DOI: https://doi.org/10.1038/nbt1196-1549
This article is cited by
-
The Role of Secretory Phospholipase A2 in the Central Nervous System and Neurological Diseases
Molecular Neurobiology (2014)
-
Possible Pathophysiological Role of Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinases (MMPs) in Metastatic Brain Tumor-associated Intracerebral Hemorrhage
Journal of Neuro-Oncology (2006)
-
The importance of voltage-dependent sodium channels in cerebral ischaemia
Amino Acids (1998)
